EUCTR2018-004888-31-NL
Active, not recruiting
Phase 1
ong-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies - Adoptive cell therapy LTFU study
ConditionsSynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Synovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcoma
- Sponsor
- GlaxoSmithKline research & development Ltd.
- Enrollment
- 171
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type of Participant and Disease Characteristics
- •1\. Participants who:
- •a. Have received at least one infusion of a GSK adoptive cell therapy
- •b. Have completed a GSK sponsored or suported interventional study or have withdrawn from it, as defined in the interventional protocol
- •c. have completed treatment as part of managed access to a GSK adoptive cell therapy
- •Participants who complete an interventional study will complete the assessments
- •outlined in the interventional protocol prior to starting on this study.
- •2\. Male or Female participants. Contraceptive use by men or women should be
- •consistent with local regulations regarding the methods of contraception for those
- •participating in clinical studies.
Exclusion Criteria
- •Not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-513033-21-00Adaptimmune LLC76
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004888-31-FRGlaxoSmithKline Research & Development Ltd171
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004888-31-SEAdaptimmune LLC171
Not yet recruiting
Phase 2
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies (study 208750)cancertumors10027655NL-OMON52738Adaptimmune LLC1
Active, not recruiting
Phase 1
ong term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation.EUCTR2011-001078-25-GBational Institute of Health, National Eye Institute250